|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
|
|---|---|---|---|---|---|
| Cash | |||||
| Advance – related party | |||||
| Prepaid expenses | |||||
| Total Current Assets | |||||
| Deferred offering costs | |||||
| Investments held in Trust Account | |||||
| Total Assets | |||||
| Accrued expenses | |||||
| Promissory note – related party | |||||
| Total Current Liabilities | |||||
| Deferred underwriting fee payable | |||||
| Total Liabilities | |||||
| Ordinary shares subject to possible redemption, 8,280,000 shares and 0 shares at redemption value of $10.25 and $0 per share as of March 31, 2026 and March 31, 2025, respectively | |||||
| Ordinary shares subject to possible redemption, $0.0001 par value, 8,280,000 shares at redemption value of $10.34 per share | |||||
| Ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 3,126,650 shares and outstanding (excluding 8,280,000 shares subject to possible redemption) | |||||
| Additional paid-in capital | |||||
| Accumulated deficit | |||||
| Total Shareholders’ (Deficit) Equity | |||||
| Total Shareholders’ Deficit | |||||
| Total Liabilities, Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
